^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

KappaMab

i
Other names: MDX-1097 (kappa), KappaMab, MDX-1097, IST-1097
Company:
HaemaLogiX
Drug class:
NK cell stimulant, κ myeloma antigen inhibitor
Related drugs:
12ms
Changes in immune cell populations following KappaMab, lenalidomide and low-dose dexamethasone treatment in multiple myeloma. (PubMed, Clin Transl Immunology)
These data characterise the effects of LEN, DEX, and KM treatment on non-target immune cells in MM. Treatment may support destruction of MM cells by both direct action and indirect mechanisms via immune cells.
Journal • Immune cell
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
lenalidomide • KappaMab
1year
Novel antigens LMA and KMA are expressed on malignant bone marrow plasma cells from patients at all stages of multiple myeloma and in other plasma cell dyscrasias (IMW 2023)
KappaMab (formerly MDX-1097) clinical trials have confirmed that normal leukocytes are not depleted by the antibody with no on-target off-tumour effects1-3, and preclinical KMA.CAR T cell data has confirmed the antibody specificity4. KMA or LMA are expressed on PCs at all stages of MM, and all plasmacytomas and AL patient samples. The increased Ag densities of both KMA and LMA compared to BCMA on RRMM BM PCs indicates antigen persistence on a treatment resistant clone. The combination of increased and persistent antigen density and the specificity of these therapeutic antibodies could provide a significant benefit in the treatment of myeloma and PCDs.1.
Clinical • IO biomarker
|
TNFRSF17 (TNF Receptor Superfamily Member 17) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • SLAMF7 (SLAM Family Member 7)
|
KappaMab • KMA.CAR T
1year
A Novel CAR-T cell therapy targeting kappa myeloma antigen for the treatment of multiple myeloma (IMW 2023)
Chimeric Antigen Receptor (CAR)-T cell therapy has recently entered the standard of care for relapsed and refractory MM, following the recent FDA-approval of two CAR-T cell products, ide-cel® and cilta-cel®, which target the B cell maturation antigen (BCMA)...The monoclonal antibody, KappaMab (MDX-1097), binds to a conformational epitope on KMA, and has been assessed in phase I, IIa and IIb clinical trials in relapse refractory myeloma patients... Our data demonstrates that anti-KMA CAR-T cell therapy is a novel and potent treatment ready to enter a phase I clinical trial for patients with multiple myeloma.
CAR T-Cell Therapy • IO biomarker
|
IFNG (Interferon, gamma)
|
Abecma (idecabtagene vicleucel) • Carvykti (ciltacabtagene autoleucel) • KappaMab • KMA.CAR T
over1year
A sequential cohort study evaluating single-agent KappaMab and KappaMab combined with lenalidomide and low-dose dexamethasone in relapsed and/or refractory kappa light chain-restricted multiple myeloma (AMaRC 01-16). (PubMed, Br J Haematol)
Both single-agent KM and KM-Rd regimens were well tolerated, with the KM-Rd safety profile similar to patients given only Rd in other clinical settings. Based on the excellent safety profile and significant efficacy, further clinical trials escalating the KM dose and pairing KM with other standard-of-care treatments are planned.
Journal
|
lenalidomide • dexamethasone • KappaMab
over1year
Cellular immunotherapy targeting kappa myeloma antigen for the treatment of multiple myeloma (AACR 2023)
Chimeric Antigen Receptor (CAR)-T cell therapy has recently entered the standard of care for relapsed and refractory MM, following the recent FDA-approval of two CAR-T cell products, ide-cel® and cilta-cel®, which target the B cell maturation antigen (BCMA)...The monoclonal antibody, KappaMab (MDX-1097), binds to a conformational epitope on KMA, and has been assessed in phase I, IIa and IIb clinical trials in relapse refractory myeloma patients (1)...We successfully generated human anti-KMA CAR-T cells with high and stable CAR expression and a predominately memory T cell phenotype...(1) Spencer et al. Blood Cancer Journal (2019) 9:58
IO biomarker
|
IFNG (Interferon, gamma)
|
Abecma (idecabtagene vicleucel) • Carvykti (ciltacabtagene autoleucel) • KappaMab • KMA.CAR T
2years
Novel Antigens LMA and Kma Are Expressed on Malignant Bone Marrow Plasma Cells from Patients with Relapsed Refractory Multiple Myeloma and Plasma Cell Dyscrasias (ASH 2022)
KMA and LMA expression is independent of serum Ig and FLC levels and % marrow plasma cells. These data show that KappaMab and LambdaMab have therapeutic potential in the treatment of myeloma patients, especially in the setting of relapsed refractory disease where the combination of high antigen density and restriction of the target antigen to the malignant subpopulation of plasma cells will confer valuable clinical benefit.
Clinical • IO biomarker
|
TNFRSF17 (TNF Receptor Superfamily Member 17) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • SLAMF7 (SLAM Family Member 7)
|
KappaMab
3years
A Novel B Cell Antigen Designated Lambda Myeloma Antigen (LMA) Has Been Identified Using Two Fully Human Monoclonal Antibodies (Mabs) That Bind to Similar Epitopes on Plasma Cells from Patients with Plasma Cell Dyscrasias (ASH 2021)
Introduction: The novel kappa (κ) myeloma antigen (KMA) has been described and a specific monoclonal antibody KappaMab (formerly MDX-1097) developed which is currently in a Phase IIb clinical trial... These studies used mostly myeloma samples and a small number of other plasma cell dyscrasias. Nevertheless expression of KMA and LMA was identified on PCs across the spectrum of disease. Within the treated patient cohort the antigen density of KMA or LMA was higher than that of BCMA and implies there is an enrichment of these novel antigens in relapsed refractory myeloma.
Clinical • IO biomarker
|
TNFRSF17 (TNF Receptor Superfamily Member 17) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1)
|
CD38 expression • NCAM1 expression
|
KappaMab
3years
[VIRTUAL] Extracellular RNA: An emerging biomarker for therapeutic monitoring in multiple myeloma (IMW 2021)
We also performed droplet digital PCR (ddPCR) for exRNA transcripts of candidate biomarkers of lenalidomide (LEN) response in a “test cohort” of samples collected at study entry (baseline) and after five days of LEN treatment (C1D5) in a phase 1b trial of azacitidine in combination with LEN and dexamethasone (DEX) for patients with RR MM (ROAR trial; n= 24 patients). A “validation cohort” was obtained from a phase IIb trial of KappaMab in combination with LEN and DEX in RR MM (KappaMab trial; n=39 patients) at screening and C1D5... The data presented here provide the first demonstration of the utility of exRNA for biomarker identification and therapeutic monitoring. It provides the foundation for further exploration and development of exRNA testing as a potentially simple, non-invasive, repeatable strategy in MM.
CRBN (Cereblon) • IKZF3 (IKAROS Family Zinc Finger 3)
|
lenalidomide • azacitidine • dexamethasone • KappaMab